Presale Now Live
UTRx DAO LLC UTRx
Token Sale Stage 1
Discover how UTR Therapeutics is pioneering a new era in biotech...
Limited Time Offer
Stage 1 - Buy UTRx Now
UTRX CEO Interview – Watch Now
UTRx DAO LLC
UTR Therapeutics Inc is an IND Stage biotech company with a first-in-class technology that can overwrite any target of interest. We have proven this robustly in difficult to treat cancers and have filed IND submissions for various cancers to regulatory authorities in the US and outside of the US. This technology is also ready to scale into Neurodegenerative and rare diseases.
Our Brands
Presale Token Allocation
Tokenomics
UTRX Tokenomics - Allocation of Tokens & Distribution of Funds
Smart Contract Address
Always verify the contract address before interacting
View ContractTotal Supply
A total supply of 10 million tokens, strategically designed with deflationary protocols to preserve scarcity and enhance long-term value for holders.
UTRX Therapeutics Schedule
UTR Therapeutics Inc., led by CEO and Principal Investigator Dr. Chidiebere Awah, is driving forward a pioneering pipeline focused on aggressive cancers, Alzheimer’s disease, and metabolic disorders. In a recent interview with Susan Schulz, Dr. Awah shared insights into the company’s novel mRNA therapeutic platform and key progress in navigating regulatory pathways. Rooted in rigorous scientific research and a commitment to innovation, UTR is redefining the landscape of targeted treatments and expanding the possibilities of precision medicine for patients around the world.
Utility
The UTRX token unlocks a robust suite of benefits, including: governance rights over certain protocol and ecosystem decisions, staking rewards to incentivize long-term participation, multicurrency access using USDT, USDC, or BNB, access to premium UTRX platform features and AI-integrated tools, and participation in referral and rewards programs. To sustain ecosystem development and ensure value growth, 15% of the total 10 million UTRX supply is reserved for future partnerships, technological scaling, and platform expansion initiatives. This hybrid approach makes UTR one of the first biotech innovators to fully integrate blockchain utility with real-world clinical assets — more than a token, it's your on-chain access point to the future of therapeutic innovation, backed by science and driven by community.
FAQ
Frequently Asked Questions
Everything you need to know about UTRx Therapeutics and our innovative ecosystem.
UTR Therapeutics Inc. stands apart from other blockchain ventures by integrating cutting-edge biotechnology with decentralized finance. Unlike traditional ICOs that focus solely on digital assets, UTRX tokens represent a groundbreaking hybrid model that bridges biotech innovation with blockchain technology.
- First-in-class mRNA overwriting technology for treating deadly cancers
- Real-world asset-backed tokenization, tying blockchain to tangible biotech advancements
- Strategic creation and allocation of 10 million UTRX utility tokens, enhancing stakeholder engagement and confidence
By merging biotech breakthroughs with blockchain, UTR is redefining both industries, offering a unique opportunity for investors and stakeholders.
To learn more about our vision and investment potential, Contact us today.
Security is a top priority for UTRX token holders. We have integrated our ICO with MetaMask, one of the most trusted and widely used cryptocurrency wallets, to ensure secure and user-friendly participation in the token sale.
To further protect the integrity of our ecosystem and the interests of all participants, we have embedded advanced security logic directly into our smart contract. This includes:
- Maximum Holding Limit: Each wallet is restricted to a maximum number of UTRX tokens to prevent centralization and reduce the risk of manipulation by large holders.
- Maximum Purchase Cap: A per-wallet purchase limit is enforced during the ICO to ensure fair token distribution and deter bots or whales from accumulating disproportionate amounts.
- Audited Smart Contracts: Our contracts are thoroughly tested and externally audited to eliminate vulnerabilities and ensure transparency.
- Real-time Monitoring: Transactions and token allocations are tracked and verified in real time, helping identify and prevent any suspicious or unauthorized activity.
These layered security measures reflect our strong commitment to creating a safe, equitable, and transparent investment environment for all participants.
Additionally, in the event of any suspicious or malicious activity, our platform includes wallet blocking functionality, allowing us to immediately restrict access and protect the broader ecosystem.
Still have questions?
If your question wasn’t answered, don’t hesitate to contact our support team for assistance.
Contact SupportUTRx Token Value Growth By Stage Of Development
Project Milestones, Duration & Cost Estimates
| Stage | Objective | Duration | Cost Estimate |
|---|---|---|---|
| FDA Submission & Approval | FDA and OUS(outside of USA) IND submission already achieved | 4 years | $5M |
| Ico Initial Launch Build | Raise Money For GMP Manufacturing & Phase 1 Trial | 1 - 2 months | $100 - 200k |
| GMP Manufacturing | Preparation for manufacture of samples for clinical trial (21 patiient trial) 200 000 mg (600 Litres) | 8 - 10 months | $3.5m - 4.5m |
| IND Enablement | Process of manufacturing, extended data and results | 6 - 12 months | $200 - 400k |
| Phase I Clinical Trials | Approval of Phase 1 & execution of clinical trial phase 1 - preliminary bio marker endpoint with option for accelerated NDA | 12 - 16 months | $6m - 8m |
| Ico Exchange Launch | Raise Money For Phase II till Market & Phase manufacture | 2 - 4 months | $400 - 450k |
| Phase II | Prove efficacy and safety of the drug on 50 - 100 patients at a minimum | 24 - 48 months | 20 - 50m |
| Phase III | Validation of drug superiority, expansion of the label for other applications and combine capability | 60- 72 months | $200 - 300m |
| Manufacturing and Marketing | Scale up production and launch drug on market | 6 - 12 months post-approval | GMP cost x 5 + marketing budget (TNBC) |
Hear from Those Who've Benefited
From Our Innovation
Explore how our breakthrough cancer therapies are revolutionizing treatment and offering new hope to patients worldwide.
Chieke Ikenna
IT/Blockchain Developer
"UTRX Therapeutics' breakthrough has changed the way we approach cancer treatment. Their targeted therapy offers hope where traditional treatments fell short."